【摘要】 目的:观察厄洛替尼(特罗凯)单药二线治疗国人晚期非小细胞肺癌(NSCLC)的疗效及不良反应。方法:28例晚期NSCLC患者口服厄洛替尼150mg/d治疗,连续服用2个月后,根据RECIST标准评价其近期疗效及NCI毒性评价标准评价不良反应。结果:28例患者中PR 5例(17.86%),SD 12例(42.86%),PD 11例(39.28%),有效率(CR+PR)为17.86%;疾病控制率(CR+PR+SD)为60.72%。肿瘤进展时间(TTP)为2～11个月,中位TTP为5.7个月;中位生存期(MST)为11.5个月。主要的毒副反应为皮疹、皮肤瘙痒、腹泻和恶心,多为Ⅰ～Ⅱ度,对症处理后可缓解。结论:厄洛替尼单药二线治疗国人晚期NSCLC疗效较好,且不良反应轻微。更多还原

【Abstract】 Objective:To evaluate the efficacy and the side effect of erlotinib as the second line therapy in the treatment of patients with advanced non-small cell lung cancer(NSCLC).Methods:Twenty-eight patients with advanced NSCLC were treated with erlotinib which was given orally as a single drug at a dose of 150mg per day.The efficacy was evaluated according to RECIST criteria and the adverse events were evaluated according to NCI criteria.Results:There was no complete response(CR),partial response(PR) 17.86%,stable disease(SD) 42.86%,progressive disease(PD) 39.28%.The response rate(CR+PR) was 17.86%,the disease control rate(CR+PR+SD) was 60.72% in the 28 cases.Time to progression(TTP) was 2-11 months,and median time to progession(mTTP) was 5.7 months.Median survival time(MST) was 11.5 months.The main side effects were rash and itch of skin,diarrhea and nausea,which could be relieved by treatment.Conclusion:It is effective and feasible to treat advanced NSCLC with erlotinib as the second line therapy.更多还原